PRF Technologies (PRFX) Return on Capital Employed (2021 - 2024)
PRF Technologies (PRFX) posted quarterly Return on Capital Employed of 2729.86% for Q2 2024, up 285100.0% year-on-year from N/an in Q3 2023, and down 19.82% on a QoQ basis from 3404.55% in Q1 2024.
PRF Technologies (PRFX) Return on Capital Employed (2021 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Return on Capital Employed for 4 consecutive years, with 2729.86% the latest figure, recorded in Q2 2024.
- Quarterly Return on Capital Employed rose 285100.0% year-over-year to 2729.86% in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 2729.86% (up 285100.0% YoY) and the FY2025 annual result came in at 88.0%, up 9773200.0% from the prior year.
- Return on Capital Employed eased to 2729.86% in Q2 2024 per PRFX's latest filing, from 3404.55% in the prior quarter.
- Over the last five years, Return on Capital Employed for PRFX reached as high as 3404.55% in Q1 2024 and fell as low as 192.72% in Q4 2023.
- A 4-year average of 378.4% and a median of 40.97% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 12192 bps — and 2024, when it surged 349979 bps.
- Year by year, Return on Capital Employed stood at 38.04% in 2021, then slumped by 86 bps to 70.8% in 2022, then slumped by 172 bps to 192.72% in 2023, then surged by 1516 bps to 2729.86% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 2729.86%, 3404.55%, and 192.72% for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,729.86% |
| Mar 31, 2024 | 3,404.55% |
| Dec 31, 2023 | -192.72% |
| Sep 30, 2023 | -109.05% |
| Jun 30, 2023 | -121.14% |
| Mar 31, 2023 | -95.25% |
| Dec 31, 2022 | -70.80% |
| Sep 30, 2022 | -51.69% |
| Jun 30, 2022 | -43.11% |
| Mar 31, 2022 | -38.82% |
| Dec 31, 2021 | -38.04% |
| Sep 30, 2021 | -31.64% |
| Jun 30, 2021 | -25.47% |
| Mar 31, 2021 | -19.00% |